BioSpace News Archive

Ms. Chen, portfolio manager at Cormorant Asset Management, and Dr. Hambleton, a physician-turned-biotech executive, bring decades of experience to their new roles

Connecticut-based medical device innovator Lumendi, LLC (www.lumendi.com) has launched EZ Glide, a proprietary hydrophilic coating applied to the inner sheath of its DiLumen EIP, a double-balloon endoluminal device that aims to safely improve the navigation of the endoscope through the bowel

Lineage Cell Therapeutics Announces Vitelliform Maculopathy Patient Treated With OpRegen ® Under Named Patient Compassionate Use

entrotech life sciences, inc., an organization focused on helping healthcare professionals save lives, has released a new white paper that addresses the urgent need to expand infection surveillance and prevention efforts to include all types of vascular access devices (VAD) across care settings

Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today that it will collaborate with Emory University on a new study about the long-term effects of COVID-19 infection in the development of autoimmune diseases

Cactus Communications, a technology company accelerating scientific advancement, is proud to announce that Haruko Isomura has been appointed to the International Society for Medical Publication Professionals Certification Board as Director for the Asia-Pacific region, effective January 1, 2021.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the completion of enrollment in the Phase 1b stage of the CB4211 clinical study for nonalcoholic steatohepatitis (NASH) and obesity.

INVO Bioscience, Inc. (NASDAQ: INVO), a medical device company focused on commercializing the world’s only in vivo Intravaginal Culture System (IVC), INVOcell®, an effective and affordable treatment for patients diagnosed with infertility, announced today that it will present at the Lytham Partners Spring 2021 Investor Conference on Thursday,

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical stage company leveraging its hydrogen sulfide platform to develop next-generation safer therapies for inflammation arising from a wide range of medical conditions, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared the Company’s Investigational new drug

Escher Biomedical Diagnostics, LLC announced that its Escher BT-MED® COV19 Saliva Test has been accepted by FDA as a Notification under Section IV.C of the Emergency Use Authorization program. The BT-MED ® COV19 Test system is a high-throughput molecular method for detecting infection by the SARS-CoV-2 virus in specimens of saliva from individuals suspected of COVID-19 by their healthcare provider.